Study details
Enrolling now
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
i-SENS, Inc.
NCT IDNCT07296276ClinicalTrials.gov data as of Apr 2026
Target enrollment
32
Study length
about 3 months
Ages
18–65
Locations
4 sites in CA, GA, WA
About this study
Researchers are testing the accuracy and precision of a continuous glucose monitoring (CGM) system called CareSens Air 3 in adults with type 1 diabetes. The trial will involve inserting the CGM device twice, once as the primary insertion and again as a secondary insertion. Participants will wear the CGM for 92 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Use CareSens Air 3 primary insertion
- 2.Use CareSens Air 3 secondary insertion
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Endocrinology